<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620815</url>
  </required_header>
  <id_info>
    <org_study_id>V101P1</org_study_id>
    <secondary_id>2007-002712-25</secondary_id>
    <nct_id>NCT00620815</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above</brief_title>
  <official_title>A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years
      and above (as part of a tetravalent vaccine)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43.</measure>
    <time_frame>up to day 43</time_frame>
    <description>The antibody response was determined by SRH assay. Geometric mean areas (GMAs) and geometric mean ratios (GMRs) in the SRH assay were used to demonstrate the equivalence.
The statistical analysis was done based on the GMRs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Subjects ≤ 60 Years) With Reported Local Reactions After First Vaccination</measure>
    <time_frame>Up to 7 days after 1st vaccination</time_frame>
    <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization. The table represents local reactions after first vaccination in each arm differently.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Subjects ≤60 Years) With Reported Local Reactions After Second Vaccination</measure>
    <time_frame>Up to 7 days after 2nd vaccination</time_frame>
    <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Subjects ≤ 60 Years) With Reported Systemic Reactions After 1st and 2nd Vaccinations.</measure>
    <time_frame>7 days after 1st and 2nd vaccinations each</time_frame>
    <description>Systemic reactions were collected upto 7 days after 1st and 2nd vaccinations. All subjects were instructed to complete a diary card to record systemic reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving Seroconversion/Significant Increase in Antibody Titre/ Area as Measured by SRH and (HI) and at Least 4 Fold Rise in Titres by Micro-neutralization (MN) Assay-H5N1 Strain</measure>
    <time_frame>up to day 43</time_frame>
    <description>Measurement of immunogenicity in terms of significant increase in antibody titer and Seroconversion.
Significant increase in antibody titer is defined as at least a four-fold increase from non-negative pre-vaccination serum (≥ 10) for HI or a 50% increase in area for SRH.
Seroconversion is defined as negative pre-vaccination serum / post-vaccination titer ≥40 for HI (area ≥25 mm2 for SRH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving HI/MN ≥ 1:40 and SRH Area ≥ 25^mm2</measure>
    <time_frame>Up to 43 days</time_frame>
    <description>Measurement of immunogenicity in terms of percentage of subjects achieving a titre ≥ 40/area ≥ 25mm^2 after immunization as determined by HI (Haemagglutination Inhibition), MN(Microneutralization) and SRH assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response Determined by HI and MN Assay.</measure>
    <time_frame>Up to 43 days</time_frame>
    <description>Measurement of immunogenicity in terms of Geometric mean titers (GMTs) as determined by HI and MN assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of B-cell Antibodies Against H5N1 and H1N1 After Each Vaccination.</measure>
    <time_frame>Three weeks after first vaccination (day 22) and three weeks after second vaccination (day 43)</time_frame>
    <description>The Cell Mediated Immunity (CMI) response was evaluated in a randomly selected subgroup of approximately 92 subjects from all the vaccine groups out of a total of 601 enrolled subjects.
Frequency of circulating memory B cells (MBC), capable of differentiating in vitro into cell secreting IgG (Immunoglobulin G) antibodies specific for H5N1 (the subunit from A/Vietnam/1194/2004) or for H1N1 (the subunit from A/Solomon Island/3/2006) were determined by an ELISA-coupled limiting dilution assay.The frequency of H5N1-IgG MBC and H1N1-IgG MBC was expressed as percentages (%) of total IgG producing MBC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean T-Cells Per Million Total Cells (95% CI) in Response to H5 Peptides and H5N1 Subunit</measure>
    <time_frame>Three weeks after 1st vaccination (day 22) and three weeks after 2nd vaccination (day 43)</time_frame>
    <description>Frequency and functionality of vaccine antigen-specific CD4+ (cluster of differentiation 4) T cells was assessed in peripheral blood (PBMC) taken at days 1, 22 and 43 after in vitro stimulation with:
Library of 70 peptides spanning the whole H5 A/Vietnam/1194/2004 protein (H5 pool of 70 Vietnam) H5N1 subunit from A/Vietnam/1194/2004 (H5N1 Vietnam) H3N2 subunit from A/ Wisconsin/67/2005 (H3N2 Wisconsin) H1N1 subunit from A/Solomon Islands/3/2006 (H1N1 Solomon Islands) Polyclonal stimulus agonistic aCD3 mAb [monoclonal antibody (aCD3)].
The change in frequency of T-cells was measured.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">601</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>T/P-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/P-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/S-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T/P-A (V2 blood draw)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/P-T (V2 blood draw)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/S-A (V2 blood draw)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine</intervention_name>
    <description>Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.</description>
    <arm_group_label>T/P-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1</intervention_name>
    <description>Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.</description>
    <arm_group_label>A/P-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine</intervention_name>
    <description>Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.</description>
    <arm_group_label>A/S-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1</intervention_name>
    <description>Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.</description>
    <arm_group_label>A/P-T (V2 blood draw)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine</intervention_name>
    <description>Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.</description>
    <arm_group_label>A/S-A (V2 blood draw)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine</intervention_name>
    <description>Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.</description>
    <arm_group_label>T/P-A (V2 blood draw)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (aged 18 years and above) who have signed an informed consent form

        Exclusion Criteria:

          -  Any acute or chronic illness

          -  Receipt of seasonal influenza vaccine for the current season 2007/2008

          -  Known or suspected impairment/alteration of immune function

          -  Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination
             within 3 weeks following the last study vaccination

          -  Any serious disease

          -  Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral
             protein,neomycin or kanamycin or any other component of the study vaccine

          -  Receipt of blood, blood products or immunoglobulins 3 months prior to vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ATRIUM Gesundheitszentrum;</name>
      <address>
        <city>Holzkirchen</city>
        <zip>83607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medicine &amp; Public Health Dept. of Infect. Diseases</name>
      <address>
        <city>Munich</city>
        <zip>80799</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>July 4, 2011</results_first_submitted>
  <results_first_submitted_qc>September 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2012</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>avian flu</keyword>
  <keyword>seasonal influenza vaccine</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>prepandemic vaccine</keyword>
  <keyword>virus strain with the potential to cause pandemic</keyword>
  <keyword>tetravalent vaccine</keyword>
  <keyword>Prophylaxis of influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 2 sites in Germany</recruitment_details>
      <pre_assignment_details>All subjects were included in the trial. The data entered is for the overall study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T/P-A</title>
          <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
        </group>
        <group group_id="P2">
          <title>A/P-T</title>
          <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
        </group>
        <group group_id="P3">
          <title>A/S-A</title>
          <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrolment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T/P-A</title>
          <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
        </group>
        <group group_id="B2">
          <title>A/P-T</title>
          <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
        </group>
        <group group_id="B3">
          <title>A/S-A</title>
          <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal(S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="199"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="199"/>
            <count group_id="B4" value="601"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>A total of 601 subjects were enrolled and randomized, 199 to the T/P-A group, 203 to the A/P-T group and 199 to the A/S-A group. One subject in the A/S-A group did not meet entry criteria and so did not receive any vaccination.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196" spread="8"/>
                    <measurement group_id="B2" value="202" spread="9.8"/>
                    <measurement group_id="B3" value="198" spread="9.6"/>
                    <measurement group_id="B4" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 61 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="1"/>
                    <measurement group_id="B2" value="1" spread="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Analysis was done on Full Analysis Set</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female (≤60 years of age)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (≤60 years of age)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (≥61 years of age)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (≥61 years of age)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43.</title>
        <description>The antibody response was determined by SRH assay. Geometric mean areas (GMAs) and geometric mean ratios (GMRs) in the SRH assay were used to demonstrate the equivalence.
The statistical analysis was done based on the GMRs.</description>
        <time_frame>up to day 43</time_frame>
        <population>The analysis was done on Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22</description>
          </group>
        </group_list>
        <measure>
          <title>To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43.</title>
          <description>The antibody response was determined by SRH assay. Geometric mean areas (GMAs) and geometric mean ratios (GMRs) in the SRH assay were used to demonstrate the equivalence.
The statistical analysis was done based on the GMRs.</description>
          <population>The analysis was done on Per Protocol Set (PPS)</population>
          <units>Area (mm^2)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="4.17" upper_limit="5.17"/>
                    <measurement group_id="O2" value="4.10" lower_limit="3.69" upper_limit="4.56"/>
                    <measurement group_id="O3" value="4.61" lower_limit="4.14" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (N= 31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O2" value="12" lower_limit="8.51" upper_limit="16"/>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=181, 189, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="36" upper_limit="47"/>
                    <measurement group_id="O2" value="35" lower_limit="31" upper_limit="40"/>
                    <measurement group_id="O3" value="39" lower_limit="34" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(On day 1) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Group Mean Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 1) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>1.01</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 1)Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(On day 22) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>1.19</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 22) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>0.85</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 22) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>0.71</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(On day 43) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>1.14</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 43) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>1.05</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(On day 43) Null hypothesis representing non-equivalence was rejected if the two-sided (1-2α)*100% CI on one GMA ratio is completely within the equivalence range [0.5, 2.0].</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show statistical equivalence was, confidence intervals (CIs) of all 3 pair wise ratios of the GMAs were inspected.</non_inferiority_desc>
            <param_type>Geometric Mean Ratios</param_type>
            <param_value>0.92</param_value>
            <ci_percent>96.67</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Subjects ≤ 60 Years) With Reported Local Reactions After First Vaccination</title>
        <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization. The table represents local reactions after first vaccination in each arm differently.</description>
        <time_frame>Up to 7 days after 1st vaccination</time_frame>
        <population>The analysis was performed on Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A: In Arm Receiving Tetravalent Vaccine (T)</title>
            <description>Local reactions after first vaccination in arm receiving tetravalent influenza vaccine in group receiving one dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22</description>
          </group>
          <group group_id="O2">
            <title>T/P-A: In Arm Receiving Placebo (P)</title>
            <description>Local reactions after first vaccination in arm receiving placebo in group receiving one dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22</description>
          </group>
          <group group_id="O3">
            <title>A/P-T: In Arm Receiving Aflunov (A)</title>
            <description>Local reactions after first vaccination in arm receiving Aflunov in group receiving one dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine(T) on day 22</description>
          </group>
          <group group_id="O4">
            <title>A/P-T: In Arm Receiving Placebo (P)</title>
            <description>Local reactions after first vaccination in arm receiving Placebo in group receiving one dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22</description>
          </group>
          <group group_id="O5">
            <title>A/S-A: In Arm Receiving Aflunov (A)</title>
            <description>Local reactions after first vaccination in arm receiving Aflunov in group receiving one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) bon day 22</description>
          </group>
          <group group_id="O6">
            <title>A/S-A: In Arm Receiving Seasonal Influenza Vaccine (S)</title>
            <description>Local reactions after first vaccination in arm receiving seasonal influenza vaccination in group receiving one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Subjects ≤ 60 Years) With Reported Local Reactions After First Vaccination</title>
          <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization. The table represents local reactions after first vaccination in each arm differently.</description>
          <population>The analysis was performed on Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="197"/>
                <count group_id="O6" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="131"/>
                    <measurement group_id="O6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Subjects ≤60 Years) With Reported Local Reactions After Second Vaccination</title>
        <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
        <time_frame>Up to 7 days after 2nd vaccination</time_frame>
        <population>The analysis was performed on Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal(S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Subjects ≤60 Years) With Reported Local Reactions After Second Vaccination</title>
          <description>Local reactions were collected up to 7 days after 1st vaccinations. All subjects were instructed to complete a diary card to record local reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
          <population>The analysis was performed on Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (N=188,192,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Subjects ≤ 60 Years) With Reported Systemic Reactions After 1st and 2nd Vaccinations.</title>
        <description>Systemic reactions were collected upto 7 days after 1st and 2nd vaccinations. All subjects were instructed to complete a diary card to record systemic reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
        <time_frame>7 days after 1st and 2nd vaccinations each</time_frame>
        <population>The analysis was performed on Per Protocol Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A: After 1st Vaccination</title>
            <description>Systemic reactions after first vaccination after one dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed 3 to 5 weeks later by Aflunov (A)</description>
          </group>
          <group group_id="O2">
            <title>A/P-T: After 1st Vaccination</title>
            <description>Systemic reactions after first vaccination after one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed 3 to 5 weeks later by tetravalent influenza vaccine (T)</description>
          </group>
          <group group_id="O3">
            <title>A/S-A: After 1st Vaccination</title>
            <description>Systemic reactions after first vaccination after one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed 3 to 5 weeks later by Aflunov (A)</description>
          </group>
          <group group_id="O4">
            <title>T/P-A: After 2nd Vaccination</title>
            <description>Systemic reactions after second vaccination after one dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed 3 to 5 weeks later by Aflunov (A)</description>
          </group>
          <group group_id="O5">
            <title>A/P-T: After 2nd Vaccination</title>
            <description>Systemic reactions after second vaccination after one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed 3 to 5 weeks later by tetravalent influenza vaccine (T)</description>
          </group>
          <group group_id="O6">
            <title>A/S-A: After 2nd Vaccination</title>
            <description>Systemic reactions after second vaccination after one dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed 3 to 5 weeks later by Aflunov (A)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Subjects ≤ 60 Years) With Reported Systemic Reactions After 1st and 2nd Vaccinations.</title>
          <description>Systemic reactions were collected upto 7 days after 1st and 2nd vaccinations. All subjects were instructed to complete a diary card to record systemic reactions starting on the day of vaccination (after 6 hours) and for each of the 6 days following each immunization.</description>
          <population>The analysis was performed on Per Protocol Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="196"/>
                <count group_id="O4" value="188"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chills (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=195, 201, 196, 187, 192, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coughing (N=195,201,196,187,192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;= 38 C) [N=195,201,195,188,192,192]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. (&lt; 38C)[N=195,201,195,188,192,192]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="200"/>
                    <measurement group_id="O3" value="192"/>
                    <measurement group_id="O4" value="186"/>
                    <measurement group_id="O5" value="187"/>
                    <measurement group_id="O6" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home due to reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic, Antipyretic Medicines Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving Seroconversion/Significant Increase in Antibody Titre/ Area as Measured by SRH and (HI) and at Least 4 Fold Rise in Titres by Micro-neutralization (MN) Assay-H5N1 Strain</title>
        <description>Measurement of immunogenicity in terms of significant increase in antibody titer and Seroconversion.
Significant increase in antibody titer is defined as at least a four-fold increase from non-negative pre-vaccination serum (≥ 10) for HI or a 50% increase in area for SRH.
Seroconversion is defined as negative pre-vaccination serum / post-vaccination titer ≥40 for HI (area ≥25 mm2 for SRH)</description>
        <time_frame>up to day 43</time_frame>
        <population>The population was analyzed on per protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving Seroconversion/Significant Increase in Antibody Titre/ Area as Measured by SRH and (HI) and at Least 4 Fold Rise in Titres by Micro-neutralization (MN) Assay-H5N1 Strain</title>
          <description>Measurement of immunogenicity in terms of significant increase in antibody titer and Seroconversion.
Significant increase in antibody titer is defined as at least a four-fold increase from non-negative pre-vaccination serum (≥ 10) for HI or a 50% increase in area for SRH.
Seroconversion is defined as negative pre-vaccination serum / post-vaccination titer ≥40 for HI (area ≥25 mm2 for SRH)</description>
          <population>The population was analyzed on per protocol set.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion/significant rise SRH(N=181,189,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O2" value="86" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="O3" value="86" lower_limit="80" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion/significant rise HI (N=180,186,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="62" upper_limit="76"/>
                    <measurement group_id="O2" value="67" lower_limit="59" upper_limit="73"/>
                    <measurement group_id="O3" value="75" lower_limit="68" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four fold increase MN (N=181,189,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O2" value="86" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="O3" value="89" lower_limit="84" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving HI/MN ≥ 1:40 and SRH Area ≥ 25^mm2</title>
        <description>Measurement of immunogenicity in terms of percentage of subjects achieving a titre ≥ 40/area ≥ 25mm^2 after immunization as determined by HI (Haemagglutination Inhibition), MN(Microneutralization) and SRH assay.</description>
        <time_frame>Up to 43 days</time_frame>
        <population>The analysis was done on Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving HI/MN ≥ 1:40 and SRH Area ≥ 25^mm2</title>
          <description>Measurement of immunogenicity in terms of percentage of subjects achieving a titre ≥ 40/area ≥ 25mm^2 after immunization as determined by HI (Haemagglutination Inhibition), MN(Microneutralization) and SRH assay.</description>
          <population>The analysis was done on Per Protocol Set</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SRH-Day 1 (N=194,202,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH-Day 43 (N=181,189,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O2" value="86" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="O3" value="89" lower_limit="84" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI-Day 1 (N=192,198,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI-Day 43 (N=181,187,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="62" upper_limit="76"/>
                    <measurement group_id="O2" value="66" lower_limit="59" upper_limit="73"/>
                    <measurement group_id="O3" value="74" lower_limit="67" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN-Day 1 (N=194,202,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN-Day 43 (N=181,189,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="85" upper_limit="94"/>
                    <measurement group_id="O2" value="87" lower_limit="82" upper_limit="92"/>
                    <measurement group_id="O3" value="89" lower_limit="84" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response Determined by HI and MN Assay.</title>
        <description>Measurement of immunogenicity in terms of Geometric mean titers (GMTs) as determined by HI and MN assay.</description>
        <time_frame>Up to 43 days</time_frame>
        <population>The population was analyzed on Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response Determined by HI and MN Assay.</title>
          <description>Measurement of immunogenicity in terms of Geometric mean titers (GMTs) as determined by HI and MN assay.</description>
          <population>The population was analyzed on Per protocol set</population>
          <units>titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" lower_limit="5.49" upper_limit="6.40"/>
                    <measurement group_id="O2" value="5.58" lower_limit="5.18" upper_limit="6.02"/>
                    <measurement group_id="O3" value="5.85" lower_limit="5.42" upper_limit="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI-Day 22 (N=31,31,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" lower_limit="5.79" upper_limit="12"/>
                    <measurement group_id="O2" value="6.76" lower_limit="4.68" upper_limit="9.77"/>
                    <measurement group_id="O3" value="9.66" lower_limit="6.65" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI-Day 43 (N=181,187,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="30" upper_limit="70"/>
                    <measurement group_id="O2" value="33" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="O3" value="49" lower_limit="32" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN-Day 1 (N=194,202,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.28" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9.67" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.55" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN-Day 22 (N=31,31,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O3" value="17" lower_limit="13" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN-Day 43 (N=181,189,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" lower_limit="110" upper_limit="180"/>
                    <measurement group_id="O2" value="111" lower_limit="87" upper_limit="141"/>
                    <measurement group_id="O3" value="133" lower_limit="105" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of B-cell Antibodies Against H5N1 and H1N1 After Each Vaccination.</title>
        <description>The Cell Mediated Immunity (CMI) response was evaluated in a randomly selected subgroup of approximately 92 subjects from all the vaccine groups out of a total of 601 enrolled subjects.
Frequency of circulating memory B cells (MBC), capable of differentiating in vitro into cell secreting IgG (Immunoglobulin G) antibodies specific for H5N1 (the subunit from A/Vietnam/1194/2004) or for H1N1 (the subunit from A/Solomon Island/3/2006) were determined by an ELISA-coupled limiting dilution assay.The frequency of H5N1-IgG MBC and H1N1-IgG MBC was expressed as percentages (%) of total IgG producing MBC.</description>
        <time_frame>Three weeks after first vaccination (day 22) and three weeks after second vaccination (day 43)</time_frame>
        <population>The analysis was done on Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal(S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of B-cell Antibodies Against H5N1 and H1N1 After Each Vaccination.</title>
          <description>The Cell Mediated Immunity (CMI) response was evaluated in a randomly selected subgroup of approximately 92 subjects from all the vaccine groups out of a total of 601 enrolled subjects.
Frequency of circulating memory B cells (MBC), capable of differentiating in vitro into cell secreting IgG (Immunoglobulin G) antibodies specific for H5N1 (the subunit from A/Vietnam/1194/2004) or for H1N1 (the subunit from A/Solomon Island/3/2006) were determined by an ELISA-coupled limiting dilution assay.The frequency of H5N1-IgG MBC and H1N1-IgG MBC was expressed as percentages (%) of total IgG producing MBC.</description>
          <population>The analysis was done on Full analysis set</population>
          <units>Percentages of B-cell antibodies</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H5N1-IgG MBC - Day 1 (N=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.11" upper_limit="1.28"/>
                    <measurement group_id="O2" value="0.42" lower_limit="-0.168" upper_limit="1.01"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-0.073" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5N1-IgG MBC - Day 22 (N=30, 30, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" lower_limit="2.66" upper_limit="8.11"/>
                    <measurement group_id="O2" value="6.08" lower_limit="3.36" upper_limit="8.8"/>
                    <measurement group_id="O3" value="7.58" lower_limit="4.77" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5N1-IgG MBC - Day 43 (N=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" lower_limit="4.71" upper_limit="8.64"/>
                    <measurement group_id="O2" value="7.21" lower_limit="5.24" upper_limit="9.18"/>
                    <measurement group_id="O3" value="6.84" lower_limit="4.84" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1-IgG MBC - Day 1 (N=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="0.81" upper_limit="3.89"/>
                    <measurement group_id="O2" value="2.64" lower_limit="1.1" upper_limit="4.18"/>
                    <measurement group_id="O3" value="1.61" lower_limit="0.039" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1-IgG MBC - Day 22 (N=30, 30, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.29" upper_limit="17"/>
                    <measurement group_id="O2" value="8.55" lower_limit="4.76" upper_limit="12"/>
                    <measurement group_id="O3" value="15" lower_limit="11" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1-IgG MBC - Day 43 (N=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6.98" upper_limit="17"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O3" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean T-Cells Per Million Total Cells (95% CI) in Response to H5 Peptides and H5N1 Subunit</title>
        <description>Frequency and functionality of vaccine antigen-specific CD4+ (cluster of differentiation 4) T cells was assessed in peripheral blood (PBMC) taken at days 1, 22 and 43 after in vitro stimulation with:
Library of 70 peptides spanning the whole H5 A/Vietnam/1194/2004 protein (H5 pool of 70 Vietnam) H5N1 subunit from A/Vietnam/1194/2004 (H5N1 Vietnam) H3N2 subunit from A/ Wisconsin/67/2005 (H3N2 Wisconsin) H1N1 subunit from A/Solomon Islands/3/2006 (H1N1 Solomon Islands) Polyclonal stimulus agonistic aCD3 mAb [monoclonal antibody (aCD3)].
The change in frequency of T-cells was measured.</description>
        <time_frame>Three weeks after 1st vaccination (day 22) and three weeks after 2nd vaccination (day 43)</time_frame>
        <population>Analysis was done on full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>T/P-A</title>
            <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
          </group>
          <group group_id="O2">
            <title>A/P-T</title>
            <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
          </group>
          <group group_id="O3">
            <title>A/S-A</title>
            <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
          </group>
        </group_list>
        <measure>
          <title>Mean T-Cells Per Million Total Cells (95% CI) in Response to H5 Peptides and H5N1 Subunit</title>
          <description>Frequency and functionality of vaccine antigen-specific CD4+ (cluster of differentiation 4) T cells was assessed in peripheral blood (PBMC) taken at days 1, 22 and 43 after in vitro stimulation with:
Library of 70 peptides spanning the whole H5 A/Vietnam/1194/2004 protein (H5 pool of 70 Vietnam) H5N1 subunit from A/Vietnam/1194/2004 (H5N1 Vietnam) H3N2 subunit from A/ Wisconsin/67/2005 (H3N2 Wisconsin) H1N1 subunit from A/Solomon Islands/3/2006 (H1N1 Solomon Islands) Polyclonal stimulus agonistic aCD3 mAb [monoclonal antibody (aCD3)].
The change in frequency of T-cells was measured.</description>
          <population>Analysis was done on full analysis set</population>
          <units>Mean cells per million total cells</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H5 Pool of 70 Vietnam Day 1 (N=30, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="106" upper_limit="218"/>
                    <measurement group_id="O2" value="175" lower_limit="120" upper_limit="230"/>
                    <measurement group_id="O3" value="167" lower_limit="111" upper_limit="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5 Pool of 70 Vietnam Day 22 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273" lower_limit="198" upper_limit="348"/>
                    <measurement group_id="O2" value="358" lower_limit="284" upper_limit="431"/>
                    <measurement group_id="O3" value="365" lower_limit="290" upper_limit="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5 Pool of 70 Vietnam Day 43 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311" lower_limit="246" upper_limit="376"/>
                    <measurement group_id="O2" value="328" lower_limit="264" upper_limit="392"/>
                    <measurement group_id="O3" value="290" lower_limit="225" upper_limit="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5N1 Vietnam Day 1 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" lower_limit="93" upper_limit="178"/>
                    <measurement group_id="O2" value="180" lower_limit="137" upper_limit="222"/>
                    <measurement group_id="O3" value="155" lower_limit="112" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5N1 Vietnam Day 22 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604" lower_limit="420" upper_limit="788"/>
                    <measurement group_id="O2" value="711" lower_limit="526" upper_limit="895"/>
                    <measurement group_id="O3" value="938" lower_limit="752" upper_limit="1124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H5N1 Vietnam Day 43 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784" lower_limit="615" upper_limit="952"/>
                    <measurement group_id="O2" value="813" lower_limit="644" upper_limit="982"/>
                    <measurement group_id="O3" value="750" lower_limit="579" upper_limit="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Wisconsin Day 1 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" lower_limit="266" upper_limit="392"/>
                    <measurement group_id="O2" value="344" lower_limit="281" upper_limit="407"/>
                    <measurement group_id="O3" value="349" lower_limit="285" upper_limit="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Wisconsin Day 22 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" lower_limit="853" upper_limit="1247"/>
                    <measurement group_id="O2" value="616" lower_limit="419" upper_limit="813"/>
                    <measurement group_id="O3" value="1129" lower_limit="929" upper_limit="1329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Wisconsin Day 43 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="910" lower_limit="750" upper_limit="1071"/>
                    <measurement group_id="O2" value="1034" lower_limit="874" upper_limit="1195"/>
                    <measurement group_id="O3" value="814" lower_limit="651" upper_limit="978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Solomon Islands Day 1 (N=30, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275" lower_limit="186" upper_limit="365"/>
                    <measurement group_id="O2" value="427" lower_limit="339" upper_limit="515"/>
                    <measurement group_id="O3" value="331" lower_limit="241" upper_limit="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Solomon Islands Day 22 (N=30, 30, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="998" lower_limit="795" upper_limit="1201"/>
                    <measurement group_id="O2" value="729" lower_limit="528" upper_limit="930"/>
                    <measurement group_id="O3" value="1040" lower_limit="842" upper_limit="1237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Solomon Islands Day 43 (N=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="930" lower_limit="735" upper_limit="1125"/>
                    <measurement group_id="O2" value="973" lower_limit="781" upper_limit="1166"/>
                    <measurement group_id="O3" value="792" lower_limit="599" upper_limit="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aCD3 Day 1 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38714" lower_limit="29922" upper_limit="47505"/>
                    <measurement group_id="O2" value="32703" lower_limit="23912" upper_limit="41494"/>
                    <measurement group_id="O3" value="27824" lower_limit="18887" upper_limit="36760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aCD3 Day 22 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29134" lower_limit="26356" upper_limit="31911"/>
                    <measurement group_id="O2" value="27324" lower_limit="24571" upper_limit="30077"/>
                    <measurement group_id="O3" value="32324" lower_limit="29504" upper_limit="35144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aCD3 Day 43 (N=31, 31, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31001" lower_limit="27850" upper_limit="34153"/>
                    <measurement group_id="O2" value="29327" lower_limit="26203" upper_limit="32451"/>
                    <measurement group_id="O3" value="34680" lower_limit="31480" upper_limit="37880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period</time_frame>
      <desc>Data provided in the &quot;other Adverse Events (&gt;5%)&quot; includes solicited local and systemic reactions along with unsolicited Adverse Events (AEs) that persisted for more than 7 days after each study vaccination. Events not otherwise noted as occurring in the &gt;= 61 year old population were limited to the &lt;= 60 year old population.</desc>
      <group_list>
        <group group_id="E1">
          <title>T/P-A</title>
          <description>one dose of the tetravalent (T) influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by Aflunov, on study day 22</description>
        </group>
        <group group_id="E2">
          <title>A/P-T</title>
          <description>one dose of the Aflunov (A; A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, with one dose of the placebo (P) control, on study day 1, followed by the tetravalent (T) influenza vaccine, on study day 22</description>
        </group>
        <group group_id="E3">
          <title>A/S-A</title>
          <description>one dose of the Aflunov (A, A/H5N1) avian influenza vaccine administered concomitantly, in a different arm, one dose of licensed seasonal (S) vaccine, on study day 1, followed by Aflunov (A), on study day 22</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Endoscopic Retrograde Cholangiopancreatography</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bulimia Nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Depression Suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eye Operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hysterosalpingo-Oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphadenectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tinea Pedis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wisdom teeth Removal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>In subjects &gt;= 61 years of age.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

